Feedback / Questions
ADCT-212 - ADC Therapeutics
ADCT-701 - ADC Therapeutics
Zynlonta (loncastuximab tesirine) - Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI
https://www.businesswire.com/news/home/20221108005150/en/ADC-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates
Nov 8, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next